SABS
HealthcareSAB Biotherapeutics, Inc.
$3.74
$-0.03 (-0.80%)
Jan 5, 2026
Price History (1Y)
Analysis
SAB Biotherapeutics, Inc. (SABS) is a biotechnology company in the healthcare sector with 63 employees and a market capitalization of $178.05 million. The company's financial health is characterized by significant losses, as evidenced by a net income of -$4,288,005 and an EBITDA of -$40,087,972 over the trailing twelve months. Additionally, the operating margin stands at -37,657.1% and the profit margin at 16,338.3%. On the other hand, SABS has generated revenue of $114,698 over the same period. The company's balance sheet shows a debt-to-equity ratio of 3.75 and cash reserves of $110.88 million. SAB Biotherapeutics' valuation metrics include a forward P/E ratio of -12.47, an EV/EBITDA of -1.87, and a price-to-book ratio of 1.08. The company's price-to-sales ratio is 1552.33, indicating significant multiples over revenue. Dividend information is not applicable.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders. It has applied advanced genetic engineering to develop transchromosomic for hyperimmunization and plasma collection, as well as develops product to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 2b clinical trials in delaying the onset or progression of type 1. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.
Visit website →Key Statistics
- Market Cap
- $178.05M
- P/E Ratio
- N/A
- 52-Week High
- $6.60
- 52-Week Low
- $1.00
- Avg Volume
- 265.62K
- Beta
- 0.59
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- United States
- Employees
- 63